DERMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Journey Medical Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$5.17+0.21 (+4.13%)
Close on Oct 19, 2026
- Market cap
- $142.14M
- P/E (TTM)
- –
- Dividend yield
- –
Journey Medical Corp revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|
| Qbrexza | $25.01M | $25.11M | $25.41M | – | – | 40.4% | -0.4% |
| Emrosi | $14.75M | – | – | – | – | 23.8% | – |
| Accutane | $12.88M | $19.41M | $20.17M | $10.05M | – | 20.8% | -33.6% |
| Foam franchise products (Amzeeq & Zilxi) | $5.86M | $6.65M | – | – | – | 9.5% | -11.9% |
| Other / legacy | $2.74M | $3.96M | $5.92M | – | – | 4.4% | -30.9% |
| Ximino | – | – | – | $8.25M | $9.52M | – | – |
| Exelderm | – | – | – | $5.36M | $4.45M | – | – |
| Other branded revenue | – | – | – | $37.00K | -$148.00K | – | – |
| Targadox | – | – | – | $22.38M | $30.71M | – | – |
| Qbrexa | – | – | – | $17.06M | – | – | – |
| Zilxi | – | $1.64M | $1.96M | – | – | – | – |
| Amzeeq | – | $5.01M | $6.20M | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Journey Medical's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.